ReproCELL Group Brand
Cutting-edge research reagent provider for iPS cell from America
Efficiently and safely creates iPS cell
with a clinical application through mRNA Reprogramming, which is cutting-edge technology
Also, has the technology of more efficient and high-quality differentiation with the specialty chemical technology
One of the largest commercial human tissue banks in the world
Stocked with more than 600,000 human tissue, serum, DNA, and RNA samples, from over 120,000 patients and over 700 affiliated medical institutions all over the world
（Global BioRepository inventory by disease）
Cancer, Metabolic, Immunological Disorders, etc.
Leads rapidly growing 3D culture market
Capable of culturing in near-vivo environment and ideal conditions more than 2D cell culture
Receive much attention as a new technology in the realms of iPS cell and regenerative medicine
Biopta provides unique assay services employing fresh human tissues to support drug development
By providing contract research services to the pharmaceutical industry since 2002, Biopta has become a world leader in the use of fresh functional human tissues to better predict drug activity prior to clinical trials. Drug development risk can be minimized by predicting the safety, efficacy, absorption or metabolism of compounds in phenotypically-relevant healthy and diseased human tissues. With expertise in all areas of human tissues research including sourcing, handling and experimentation, Biopta scientists are on-hand 24/7 to work on any project as soon as fresh tissues arrives. The experienced Biopta team assists pharmaceutical researchers with protocol design and technology platform selection to ensure that data collection and results are high quality and trustworthy. And by guaranteeing strict adherence to ethical guidelines, legal requirements and GLP laboratory practices, Biopta has emerged as a trusted partner of leading pharmaceutical companies worldwide.